Self-peptides prolong survival in murine autoimmunity via reduced IL-2/IL-7-mediated STAT5 signaling, CD8 coreceptor, and Vα2 down-regulation

Journal of Immunology

Volumn 183, Issue 5, 2009, Pages 3130-3138

  Gutermuth, Jan ^a   Nograles, Kristine E ^a   Miyagawa, Fumi ^a   Nelson, Emily ^a   Cho, Young Hun ^a   Katz, Stephen I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKERATIN 14; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 7; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CD8 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; OVA 8; OVA-8; OVALBUMIN; OVALBUMIN (257 64), MOUSE; OVALBUMIN (257-64), MOUSE; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; IMMUNOMODULATION; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANIMAL; AUTOIMMUNE DISEASE; BIOSYNTHESIS; C57BL MOUSE; CHICKEN; DRUG ANTAGONISM; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MORTALITY; MOUSE MUTANT; PHYSIOLOGY; SOLUBILITY; SURVIVAL; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD8; AUTOIMMUNE DISEASES; CHICKENS; CLONAL ANERGY; DOWN-REGULATION; IMMUNE TOLERANCE; INTERLEUKIN-2; INTERLEUKIN-7; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OVALBUMIN; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIGNAL TRANSDUCTION; SOLUBILITY; STAT5 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS;

EID: 70349238795     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900793     Document Type: Article

References (36)

1. Jacobson, D. L., S. J. Gange, N. R. Rose, and N. M. Graham. 1997. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84: 223-243.
2. Eaton, W. W., N. R. Rose, A. Kalaydjian, M. G. Pedersen, and P. B. Mortensen. 2007. Epidemiology of autoimmune diseases in Denmark. J. Autoimmun. 29: 1-9.
3. h 17 cells in inflammation. Int. Immunol. 20: 1361-1368.
4. Rose, N. R., and C. Bona. 1993. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today 14: 426-430.
5. Yanaba, K., J. D. Bouaziz, T. Matsushita, C. M. Magro, E. W. St Clair, and T. F. Tedder. 2008. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223: 284-299.
6. Vandenbark, A. A., and H. Offner. 2008. Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored? Immunology 125: 1-13.
7. + T cells in autoimmunity. Curr. Opin. Immunol. 17: 624-631.
8. Liblau, R. S., F. S. Wong, L. T. Mars, and P. Santamaria. 2002. Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 17: 1-6.
9. Levesque, M. C., and E. W. St Clair. 2008. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol. 121: 13-21.
10. Larche, M., and D. C. Wrath. 2005. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11: S69-S76.
11. Aichele, P., K. Brduscha-Riem, S. Oehen, B. Odermatt, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1997. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6: 519-529.
12. Bercovici, N., A. Heurtier, C. Vizler, N. Pardigon, C. Cambouris, P. Desreumaux, and R. Liblau. 2000. Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. J. Immunol. 165: 202-210.
13. Haller, M. J., P. A. Gottlieb, and D. A. Schatz. 2007. Type 1 diabetes intervention trials 2007: where are we and where are we going? Curr. Opin. Endocrinol. Diab. Obesity 14: 283-287.
14. Achenbach, P., J. Barker, E. Bonifacio, and P.-P. S. Group. 2008. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr. Diab. Rep. 8: 87-93.
15. Vandenbark, A. A., N. E. Culbertson, R. M. Bartholomew, J. Huan, M. Agotsch, D. LaTocha, V. Yadav, M. Mass, R. Whitham, J. Lovera, et al. 2008. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 123: 66-78.
16. Correale, J., M. Farez, and W. Gilmore. 2008. Vaccines for multiple sclerosis: progress to date. CNS Drugs 22: 175-198.
17. Karl, S., and J. Ring. 1999. Pro and contra of specific hyposensitization. Eur. J. Dermatol. 9: 325-331.
18. Caspi, R. R. 2008. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. 8: 970-976.
19. + T-cell receptor transgenic T cells into keratin 14-ovalbumin transgenic mice. J. Invest. Dermatol. 123: 109-115.
20. Park, J. H., S. Adoro, P. J. Lucas, S. D. Sarafova, A. S. Alag, L. L. Doan, B. Erman, X. Liu, W. Ellmeier, R. Bosselut, et al. 2007. "Coreceptor tuning": cytokine signals transcriptionally tailor CD8 coreceptor expression to the selfspecificity of the TCR. Nat. Immunol. 8: 1049-1059.
21. Miyagawa, F., Y. Tagaya, B. S. Kim, H. J. Patel, K. Ishida, T. Ohteki, T. A. Waldmann, and S. I. Katz. 2008. IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease. J. Immunol. 181: 1109-1119.
22. Blattman, J. N., R. Antia, D. J. Sourdive, X. Wang, S. M. Kaech, K. Murali-Krishna, J. D. Altman, and R. Ahmed. 2002. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 195: 657-664.
23. Mescher, M. F., P. Agarwal, K. A. Casey, C. D. Hammerbeck, Z. Xiao, and J. M. Curtsinger. 2007. Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation. Semin. Immunol. 19: 153-161.
24. Holler, P. D., and D. M. Kranz. 2003. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18: 255-264.
25. Park, J. H., Q. Yu, B. Erman, J. S. Appelbaum, D. Montoya-Durango, H. L. Grimes, and A. Singer. 2004. Suppression of IL7Rα transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 21: 289-302.
26. McGargill, M. A., J. M. Derbinski, and K. A. Hogquist. 2000. Receptor editing in developing T cells. Nat. Immunol. 1: 336-341.
27. Jameson, S. C., K. A. Hogquist, and M. J. Bevan. 1994. Specificity and flexibility in thymic selection. Nature 369: 750-752.
28. Feinerman, O., J. Veiga, J. R. Dorfman, R. N. Germain, and G. Altan-Bonnet. 2008. Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science 321: 1081-1084.
29. Schluns, K. S., W. C. Kieper, S. C. Jameson, and L. Lefrancois. 2000. Interleukin- 7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1: 426-432.
30. von Freeden-Jeffry, U., P. Vieira, L. A. Lucian, T. McNeil, S. E. Burdach, and R. Murray. 1995. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181: 1519-1526.
31. + T cells. Immunol. Rev. 211: 81-92.
32. Schott, E., and H. L. Ploegh. 2002. Mouse MHC class I tetramers that are unable to bind to CD8 reveal the need for CD8 engagement in order to activate naive CD8 T cells. Eur. J. Immunol. 32: 3425-3434.
33. Xiao, Z., M. F. Mescher, and S. C. Jameson. 2007. Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J. Exp. Med. 204: 2667-2677.
34. Brusko, T. M., A. L. Putnam, and J. A. Bluestone. 2008. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223: 371-390.
35. McFarland, H. F., and R. Martin. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8: 913-919.
36. Veldman, C. M., K. L. Gebhard, W. Uter, R. Wassmuth, J. Grotzinger, E. Schultz, and M. Hertl. 2004. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J. Immunol. 172: 3883-3892.